Development of an intradermal or inhaled DNA vaccine for COVID-19 and beyond

开发针对 COVID-19 及其他疾病的皮内或吸入 DNA 疫苗

• 批准号: 2599978
• 金额: --
• 依托单位: University of Nottingham
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2599978
• 关键词: Development; intradermal; inhaled; DNA; vaccine

Intradermal and inhaled delivery of nucleic acid vaccines could be clinically effective, safe and globally-deployable against multiple complex diseases. This project will aim to combine physical and peptide-based delivery systems to enhance the efficacy and application of such technologies to the COVID-19 vaccine ('Covidity') presently under-development by our consortium (funded by Innovate-UK). This PhD will formulate and test combined systems for skin and lung-focused vaccine delivery in ex vivo tissue models, then move to rodent models, examining virus neutralisation, T cell responses and protection in virally challenged animals. The platform technology optimised and demonstrated will have wide ranging impact on future applications of nucleic acid vaccine approaches (including DNA, mRNA and oligo-based methods). The PhD will also directly aid attempts to translate antibody and peptide-engineering knowhow to generate a rapidly deployable and safe immunisation system for multiple complex diseases.

皮内和吸入的核酸疫苗可以在临床上有效、安全和全球部署，以对抗多种复杂的疾病。该项目旨在将物理递送系统和基于多肽的递送系统相结合，以增强此类技术的有效性并将其应用于我们的财团(由Innovate-UK资助)目前正在开发的新冠肺炎疫苗(Covidity)。这位博士将在体外组织模型中制定和测试以皮肤和肺为重点的疫苗递送组合系统，然后转移到啮齿动物模型，检查病毒中和、T细胞反应和病毒挑战动物的保护。优化和展示的平台技术将对核酸疫苗方法(包括DNA、mRNA和基于寡核苷酸的方法)的未来应用产生广泛影响。博士还将直接帮助转化抗体和肽工程技术的尝试，以产生一种针对多种复杂疾病的快速部署和安全的免疫系统。